Contineum Therapeutics Inc. - Ordinary Shares - Class A

XNAS:CTNM

11.63

-1.44 (-11.02%)

7:35:05 PM EDT: $12.52 +0.89 (+7.63%)

Market Cap (Intraday)	305.44M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$6 Million
Adjusted EPS	-$0.44

See more estimates

10-Day MA	$11.84
50-Day MA	$11.29
200-Day MA	$7.62

See more pivots

Contineum Therapeutics Inc. - Ordinary Shares - Class A Stock, XNAS:CTNM

3565 General Atomics Court, Suite 200, San Diego, California 92121

United States of America

Phone: +1.858.333.5280

Number of Employees: 41

http://www.contineum-tx.com

Description

Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company was founded by Daniel S. Lorrain on May 9, 2017 and is headquartered in San Diego, CA.